U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A "PRIOR" PATENT**

Docket Number (Optional)

029300.49991D1

In re Application of: Johannes HEBEBRAND

Application No.: 10/785,043 Filed: February 25, 2004

For: Process for Identifying Compounds Suitable for Treatment And/or Prophylaxis of Obesity

The owner*, SOLVAY PHARMACEUTICALS GmbH, of 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. 6,946,243 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior nt

patent, "as the term of said prior patent is presently shortened by any to later:	erminal disclaimer," in the event that said prior patent
expires for failure to pay a maintenance fee;	
is held unenforceable;	
is found invalid by a court of competent jurisdiction;	
is statutorily disclaimed in whole or terminally disclaimed under 37 CF	R 1.321;
has all claims canceled by a reexamination certificate; is reissued; or	
is in any manner terminated prior to the expiration of its full statutory to	erm as presently shortened by any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.	
 For submissions on behalf of an organization (e.g., corporation, petc.), the undersigned is empowered to act on behalf of the business. 	
3.3.7, and an assignment on personal action as a second second	
I hereby declare that all statements made herein of my own known	<u> </u>
information and belief are believed to be true; and further that these state	
false statements and the like so made are punishable by fine or imprison	
United States Code and that such willful false statements may jeopardize	e the validity of the application or any patent issued
thereon.	
2. X The undersigned is an attorney or Appent of record. Reg. No. 26,	269
2. 23 The undersigned is all automoty dyagrin of roodid. Trog. No. 25	, <u>200</u>
710	May 10, 2007
Signature	Date _.
J. D. Evans	2000
Typed or printed	202-624-2845
	Telephone Number
	, 5,5,6,10,12
Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become publi	ic. Credit card information should not

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this statement. See MPEP § 324.